Clinical trials: Motor Neuron Disorder
Amyotrophic Lateral Sclerosis
Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT04499963
- Testing
- Theracurmin HP
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Amyotrophic Lateral Sclerosis
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
This is a multi-center, 20-week study of inosine treatment. Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily)…
- Trial name
- SURE-ALS2 (NCT03168711)
- Testing
- Inosine
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Spinal Muscular Atrophy
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3 compared to placebo and whether the duration of…
- Trial name
- NCT01645787
- Testing
- 4-aminopyridine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis
DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty swallowing, breathing, and movement, has been found to be higher for those serving in the military than in the general population.
- Trial name
- NCT02675075
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- VA Office of Research and Development
Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to prevent progression of the disease.
- Trial name
- NCT01736553
- Where
- 15 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Amyotrophic Lateral Sclerosis
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
- Trial name
- CL211 (NCT00931944)
- Testing
- KNS-760704
- Where
- 19 sites in United States
- Volunteers
- 74 people
- Sponsor
- Knopp Biosciences
Muscular Atrophy, Spinal
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
The purpose of this open-label, single arm study is to further evaluate long-term tolerability, safety and efficacy outcomes of olesoxime in participants with Spinal Muscular Atrophy (SMA) who previously participated in one of…
- Trial name
- NCT02628743
- Testing
- Olesoxime
- Where
- 24 sites in Belgium, France and 5 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Muscle Cramps in Amyotrophic Lateral Sclerosis
Mexiletine for the Treatment of Muscle Cramps in ALS
The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01811355
- Testing
- Mexiletine
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bjorn Oskarsson, MD
Amyotrophic Lateral Sclerosis
Cervical Electrical Stimulation for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). ALS causes degeneration of motor neurons in both the brain and the spinal cord.
- Trial name
- NCT03411863
- Testing
- CES at rest, CES plus active hand or wrist movements
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Spinal Muscular Atrophy
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with…
- Trial name
- NCT01703988
- Testing
- Nusinersen
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Amyotrophic Lateral Sclerosis
Phase 3 Extension Study of Dexpramipexole in ALS
The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.
- Trial name
- ENVISION (NCT01622088)
- Testing
- Dexpramipexole
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 616 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body.
- Trial name
- tDCS_MND (NCT03293394)
- Testing
- Anodal bilateral motor cortex and cathodal spinal tDCS
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Cystic Fibrosis, Motor Neuron Disease
MN4000 for Treatment of CF and MND Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
- Conditions
- Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
- Trial name
- NCT03797677
- Testing
- MN 4000
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
- Trial name
- COURAGE-ALS (NCT04944784)
- Testing
- Reldesemtiv
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 489 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis (ALS)
Remotely Supervised tDCS for Slowing ALS Disease Progression
Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life.
- Trial name
- NCT04866771
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Illinois at Chicago
ALS, Amyotrophic Lateral Sclerosis
A Trial of Tocilizumab in ALS Subjects
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
- Trial name
- TCZALS-001 (NCT02469896)
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Barrow Neurological Institute
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT00818389
- Testing
- Lithium Carbonate, Riluzole
- Where
- 37 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Clinical Trial of High Dose CoQ10 in ALS
The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study.
- Trial name
- NCT00243932
- Testing
- coenzyme Q10
- Where
- 19 sites in United States
- Volunteers
- 185 people
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a single center, randomized, double-blind, placebo-controlled, 6-month study designed to evaluate the safety, tolerability and clinical responsiveness of MN-166/ibudilast (60 mg/day) when administered as an adjunct to…
- Trial name
- IBU-ALS-1201 (NCT02238626)
- Testing
- MN-166, riluzole
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- MediciNova